ArticleOxford medical case reports2025

Over eight years of transfusion independence with continuous erythropoietin receptor activator and Roxadustat in transfusion-dependent low-risk myelodysplastic syndrome.

Tatsuyoshi Ikenoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.